Drug intelligence / Profile preview

Yudan Shengui Capsule

Development stage: Unknown
Lead developer: Shanghai Yudan Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Yudan Shengui Capsule is a Traditional Chinese Medicine (TCM) oral formulation developed by Shanghai Yudan Pharmaceutical. It is primarily indicated for the treatment of cardiovascular and renal conditions, including coronary heart disease angina, acute myocardial infarction, and early diabetic nephropathy. The therapeutic mechanism is described in TCM terms as tonifying qi and warming yang, while simultaneously activating blood circulation and resolving blood stasis. The product is approved in China (Approval No. 国药准字 Z20000060) and is typically administered as a 0.3g oral capsule.

Brand names: Yudan Shengui Capsule玉丹参桂胶囊
Other names: Yudan Shengui Jiaonang

Targets

NF-κBTLR4 (Toll-like receptor 4)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Yudan Shengui Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yudan Shengui Capsule.

Explore the full profile